![](https://www.forex.ca/wp-content/uploads/nc-efi-placeholder-678x381.png)
BioCryst: Factor D Inhibitor Data In 2024 Should Be Watched Closely (NASDAQ:BCRX)
alvarez BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has made great progress in advancing its pipeline. That’s because it is currently evaluating the use of oral D Factor inhibitor, known as BCX10013, for the treatment of complemented mediated […]